Nivolumab (N) alone or in combination with ipilimumab (I) in patients (pts) with platinum-pretreated metastatic urothelial carcinoma (mUC), including the nivolumab 1mg/kg + ipilimumab 3mg/kg expansion from CheckMate 032
Gespeichert in:
| Veröffentlicht in: | Annals of oncology 2018-10, Vol.29, p.viii725-viii725 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | viii725 |
|---|---|
| container_issue | |
| container_start_page | viii725 |
| container_title | Annals of oncology |
| container_volume | 29 |
| creator | Rosenberg, J.E. Sharma, P. de Braud, F.G.M. Basso, U. Calvo, E. Bono, P. Morse, M. Ascierto, P.A. Lopez-Martin, J.A. Brossart, P. Rohrberg, K.S. Reguart, N. Lin, W.H. Meadows-Shropshire, S. Saci, A. Callahan, M. Siefker-Radtke, A.O. |
| description | |
| doi_str_mv | 10.1093/annonc/mdy424.038 |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed_elsev</sourceid><recordid>TN_cdi_pubmed_primary_32138000</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S092375341950429X</els_id><sourcerecordid>32138000</sourcerecordid><originalsourceid>FETCH-LOGICAL-e145t-62a5e1563748b6949d58905fd5742c53b48d5e95d944a9e77774d06068ffa45d3</originalsourceid><addsrcrecordid>eNpNkcFu3CAURVGVqpmk_YBuKpYzSp3BBjxGWVWjJI2UpptmjTA8z5AYsDCeJt_anykjt1XZIC5H713di9DHklyWRNC18j54vXbmlVXsktDmDVqUvBZFQ1h5ghZEVLTYcMpO0dk4PhFCalGJd-iUViVt8nOBfj3YQ-gnp1q8fFhh1QcPOERsPdbBtdarZIPHP23aYzvY3rqZvVsdkSH_gk8jXg5pXM3U0GfRT64YIqQIKoHBDpIaU9Y1nmJIe-it6rFWUVsfnMJL97hdfc4TdT8Z63c4I9j_c1a63fp5hy_-d0BnDV4G5cejxS4Gh7d70M_f8k5MaPUeve1UP8KHP_c5ery5_rH9Wtx_v73bfrkvoGQ8FXWlOOTY6IY1bS2YMLwRhHeGb1ilOW1ZYzgIbgRjSsAmH2ZITeqm6xTjhp6jT_PcYWodGDlE61R8lX9TzsDVDEB2cbAQ5ahzbhqMjaCTNMHKkshjp3LuVM6dytwp_Q14P5ej</addsrcrecordid><sourcetype>Index Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Nivolumab (N) alone or in combination with ipilimumab (I) in patients (pts) with platinum-pretreated metastatic urothelial carcinoma (mUC), including the nivolumab 1mg/kg + ipilimumab 3mg/kg expansion from CheckMate 032</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>Rosenberg, J.E. ; Sharma, P. ; de Braud, F.G.M. ; Basso, U. ; Calvo, E. ; Bono, P. ; Morse, M. ; Ascierto, P.A. ; Lopez-Martin, J.A. ; Brossart, P. ; Rohrberg, K.S. ; Reguart, N. ; Lin, W.H. ; Meadows-Shropshire, S. ; Saci, A. ; Callahan, M. ; Siefker-Radtke, A.O.</creator><creatorcontrib>Rosenberg, J.E. ; Sharma, P. ; de Braud, F.G.M. ; Basso, U. ; Calvo, E. ; Bono, P. ; Morse, M. ; Ascierto, P.A. ; Lopez-Martin, J.A. ; Brossart, P. ; Rohrberg, K.S. ; Reguart, N. ; Lin, W.H. ; Meadows-Shropshire, S. ; Saci, A. ; Callahan, M. ; Siefker-Radtke, A.O.</creatorcontrib><identifier>ISSN: 0923-7534</identifier><identifier>EISSN: 1569-8041</identifier><identifier>DOI: 10.1093/annonc/mdy424.038</identifier><identifier>PMID: 32138000</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><ispartof>Annals of oncology, 2018-10, Vol.29, p.viii725-viii725</ispartof><rights>2018 THE AUTHORS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,782,786,27933,27934</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32138000$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Rosenberg, J.E.</creatorcontrib><creatorcontrib>Sharma, P.</creatorcontrib><creatorcontrib>de Braud, F.G.M.</creatorcontrib><creatorcontrib>Basso, U.</creatorcontrib><creatorcontrib>Calvo, E.</creatorcontrib><creatorcontrib>Bono, P.</creatorcontrib><creatorcontrib>Morse, M.</creatorcontrib><creatorcontrib>Ascierto, P.A.</creatorcontrib><creatorcontrib>Lopez-Martin, J.A.</creatorcontrib><creatorcontrib>Brossart, P.</creatorcontrib><creatorcontrib>Rohrberg, K.S.</creatorcontrib><creatorcontrib>Reguart, N.</creatorcontrib><creatorcontrib>Lin, W.H.</creatorcontrib><creatorcontrib>Meadows-Shropshire, S.</creatorcontrib><creatorcontrib>Saci, A.</creatorcontrib><creatorcontrib>Callahan, M.</creatorcontrib><creatorcontrib>Siefker-Radtke, A.O.</creatorcontrib><title>Nivolumab (N) alone or in combination with ipilimumab (I) in patients (pts) with platinum-pretreated metastatic urothelial carcinoma (mUC), including the nivolumab 1mg/kg + ipilimumab 3mg/kg expansion from CheckMate 032</title><title>Annals of oncology</title><addtitle>Ann Oncol</addtitle><issn>0923-7534</issn><issn>1569-8041</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNpNkcFu3CAURVGVqpmk_YBuKpYzSp3BBjxGWVWjJI2UpptmjTA8z5AYsDCeJt_anykjt1XZIC5H713di9DHklyWRNC18j54vXbmlVXsktDmDVqUvBZFQ1h5ghZEVLTYcMpO0dk4PhFCalGJd-iUViVt8nOBfj3YQ-gnp1q8fFhh1QcPOERsPdbBtdarZIPHP23aYzvY3rqZvVsdkSH_gk8jXg5pXM3U0GfRT64YIqQIKoHBDpIaU9Y1nmJIe-it6rFWUVsfnMJL97hdfc4TdT8Z63c4I9j_c1a63fp5hy_-d0BnDV4G5cejxS4Gh7d70M_f8k5MaPUeve1UP8KHP_c5ery5_rH9Wtx_v73bfrkvoGQ8FXWlOOTY6IY1bS2YMLwRhHeGb1ilOW1ZYzgIbgRjSsAmH2ZITeqm6xTjhp6jT_PcYWodGDlE61R8lX9TzsDVDEB2cbAQ5ahzbhqMjaCTNMHKkshjp3LuVM6dytwp_Q14P5ej</recordid><startdate>201810</startdate><enddate>201810</enddate><creator>Rosenberg, J.E.</creator><creator>Sharma, P.</creator><creator>de Braud, F.G.M.</creator><creator>Basso, U.</creator><creator>Calvo, E.</creator><creator>Bono, P.</creator><creator>Morse, M.</creator><creator>Ascierto, P.A.</creator><creator>Lopez-Martin, J.A.</creator><creator>Brossart, P.</creator><creator>Rohrberg, K.S.</creator><creator>Reguart, N.</creator><creator>Lin, W.H.</creator><creator>Meadows-Shropshire, S.</creator><creator>Saci, A.</creator><creator>Callahan, M.</creator><creator>Siefker-Radtke, A.O.</creator><general>Elsevier Ltd</general><scope>6I.</scope><scope>AAFTH</scope><scope>NPM</scope></search><sort><creationdate>201810</creationdate><title>Nivolumab (N) alone or in combination with ipilimumab (I) in patients (pts) with platinum-pretreated metastatic urothelial carcinoma (mUC), including the nivolumab 1mg/kg + ipilimumab 3mg/kg expansion from CheckMate 032</title><author>Rosenberg, J.E. ; Sharma, P. ; de Braud, F.G.M. ; Basso, U. ; Calvo, E. ; Bono, P. ; Morse, M. ; Ascierto, P.A. ; Lopez-Martin, J.A. ; Brossart, P. ; Rohrberg, K.S. ; Reguart, N. ; Lin, W.H. ; Meadows-Shropshire, S. ; Saci, A. ; Callahan, M. ; Siefker-Radtke, A.O.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-e145t-62a5e1563748b6949d58905fd5742c53b48d5e95d944a9e77774d06068ffa45d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Rosenberg, J.E.</creatorcontrib><creatorcontrib>Sharma, P.</creatorcontrib><creatorcontrib>de Braud, F.G.M.</creatorcontrib><creatorcontrib>Basso, U.</creatorcontrib><creatorcontrib>Calvo, E.</creatorcontrib><creatorcontrib>Bono, P.</creatorcontrib><creatorcontrib>Morse, M.</creatorcontrib><creatorcontrib>Ascierto, P.A.</creatorcontrib><creatorcontrib>Lopez-Martin, J.A.</creatorcontrib><creatorcontrib>Brossart, P.</creatorcontrib><creatorcontrib>Rohrberg, K.S.</creatorcontrib><creatorcontrib>Reguart, N.</creatorcontrib><creatorcontrib>Lin, W.H.</creatorcontrib><creatorcontrib>Meadows-Shropshire, S.</creatorcontrib><creatorcontrib>Saci, A.</creatorcontrib><creatorcontrib>Callahan, M.</creatorcontrib><creatorcontrib>Siefker-Radtke, A.O.</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>PubMed</collection><jtitle>Annals of oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Rosenberg, J.E.</au><au>Sharma, P.</au><au>de Braud, F.G.M.</au><au>Basso, U.</au><au>Calvo, E.</au><au>Bono, P.</au><au>Morse, M.</au><au>Ascierto, P.A.</au><au>Lopez-Martin, J.A.</au><au>Brossart, P.</au><au>Rohrberg, K.S.</au><au>Reguart, N.</au><au>Lin, W.H.</au><au>Meadows-Shropshire, S.</au><au>Saci, A.</au><au>Callahan, M.</au><au>Siefker-Radtke, A.O.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Nivolumab (N) alone or in combination with ipilimumab (I) in patients (pts) with platinum-pretreated metastatic urothelial carcinoma (mUC), including the nivolumab 1mg/kg + ipilimumab 3mg/kg expansion from CheckMate 032</atitle><jtitle>Annals of oncology</jtitle><addtitle>Ann Oncol</addtitle><date>2018-10</date><risdate>2018</risdate><volume>29</volume><spage>viii725</spage><epage>viii725</epage><pages>viii725-viii725</pages><issn>0923-7534</issn><eissn>1569-8041</eissn><cop>England</cop><pub>Elsevier Ltd</pub><pmid>32138000</pmid><doi>10.1093/annonc/mdy424.038</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0923-7534 |
| ispartof | Annals of oncology, 2018-10, Vol.29, p.viii725-viii725 |
| issn | 0923-7534 1569-8041 |
| language | eng |
| recordid | cdi_pubmed_primary_32138000 |
| source | Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection |
| title | Nivolumab (N) alone or in combination with ipilimumab (I) in patients (pts) with platinum-pretreated metastatic urothelial carcinoma (mUC), including the nivolumab 1mg/kg + ipilimumab 3mg/kg expansion from CheckMate 032 |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-01T21%3A51%3A07IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_elsev&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Nivolumab%20(N)%20alone%20or%20in%20combination%20with%20ipilimumab%20(I)%20in%20patients%20(pts)%20with%20platinum-pretreated%20metastatic%20urothelial%20carcinoma%20(mUC),%20including%20the%20nivolumab%201mg/kg%20+%20ipilimumab%203mg/kg%20expansion%20from%20CheckMate%20032&rft.jtitle=Annals%20of%20oncology&rft.au=Rosenberg,%20J.E.&rft.date=2018-10&rft.volume=29&rft.spage=viii725&rft.epage=viii725&rft.pages=viii725-viii725&rft.issn=0923-7534&rft.eissn=1569-8041&rft_id=info:doi/10.1093/annonc/mdy424.038&rft_dat=%3Cpubmed_elsev%3E32138000%3C/pubmed_elsev%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/32138000&rft_els_id=S092375341950429X&rfr_iscdi=true |